Bullfrog AI Holdings, Inc. (BFRG)
Nasdaq · Healthcare · Health Information Services
$0.594−3.81%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $11.0M
- 52-week range
- $0.425 – $2.04
- 52-week change
- −58.80%
- EPS (trailing)
- −$0.46
Fiscal year to Dec 2025
- Revenue
- $117K
- Net income
- −$6.5M
- Operating margin
- −5652.4%
- Diluted EPS
- −$0.63
From the company’s annual report on SEC EDGAR.
About Bullfrog AI Holdings, Inc.
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
Headquarters: Gaithersburg, United States · 9 employees · bullfrogai.com